Successful long-term palliative pain management using an intrathecal catheter adapted as a lumbar drain connected to an external infusion pump: A case report Authors: Mohammad Ghalib Riziq, Ahmad Ismail Salem Ruzayqat, Mohammad Rashid Alzarir, Baraa Yousef Mohammed Alkhadrawi Published: 2026 ABSTRACT IntroductionMalignant sacral involvement can cause severe, refractory pain that remains challenging to manage with systemic analgesics alone. Intrathecal drug delivery systems (IDDS) offer an effective alternative but often involves surgically implanted pumps. We present a case in which an intrathecal catheter, typically used as a lumbar drain, was successfully adapted for long-term use with an external pump to manage intractable cancer pain.Case presentationA 54-year-old male with a history of recurrent rectosigmoid adenocarcinoma and sacral metastasis presented to the pain clinic with complaints of burning and tight pain in the lower back, buttocks, and lower extremities, associated with bilateral foot paresthesias. Pain was exacerbated by movement and significantly impacted sleep and mood. Imaging revealed a 6cm recurrent tumor invading the sacral foramina and involving the sacral nerve roots. The patient's pain remained poorly controlled despite high-dose opioids (Morphine Sulfate Tablet-Sustained Release (MST) 40 mg TID, Morphine Immediate Release (MIR) 10 mg PRN, Methadone 5 mg PO BID) and adjuvants, leading to frequent hospital admissions and emergency room (ER) visits.InterventionAfter a multidisciplinary discussion and obtaining informed patient consent, an intrathecal catheter (Lumbar Drainage Kit, Medtronic™) was inserted at the L2-L3 level under sedation and fluoroscopic guidance, with its tip positioned at T9. The catheter was tunneled subcutaneously and connected to an external ambulatory infusion pump (CADD-Solis™) via a 0.2-μm filter. A continuous infusion of bupivacaine 0.5mg/mL and fentanyl 10mcg/mL was initiated. Catheter site care was performed by the family using Chlorhexidine Gluconate dressings (3M Tegaderm™), which were changed every 7-10 days.OutcomeThe intrathecal analgesia provided sustained pain relief for 66 days, achieving a 50% reduction in pain scores and a 30% reduction in systemic opioid requirements. The patient's sleep quality and ability to reposition in bed improved. Most notably, the frequent ER visits and hospital admissions were eliminated. No signs of catheter-related infection or dislodgement occurred.ConclusionThis case demonstrates that adapting an intrathecal lumbar drain catheter for use with an external infusion pump is a feasible and effective strategy for providing long-term palliative pain control in selected patients with a good safety profile. This approach, combined with meticulous family-led catheter care, can significantly improve patients’ quality of life and reduce the burden on acute healthcare services. Introduction We present a 54-year-old male who underwent a lower anterior resection of a rectosigmoid adenocarcinoma seven years prior to presenting to our chronic pain clinic. He reported a local recurrence with sacral metastasis, presenting with constant, tight pain in the buttocks and lower back that radiated to both thighs and knees, more pronounced on the right side. The pain was associated with bilateral foot paresthesia, severe burning perianal pain, and erectile dysfunction. Notably, the pain did not involve the scrotum, and there was no urinary or fecal incontinence. The pain was scored by the patient as 10/10 on the Numeric Rating Scale (NRS). It was exacerbated by movement, such as standing or sitting, and relieved by lying flat and analgesics. The patient also reported sleep disturbance and depressive symptoms. Imaging findings were as follows A CT and multiple MRI scans showed a 6 cm recurrent extraluminal tumor at the right side of the low anterior resection anastomosis site. It extended from the colon to the perirectal and presacral spaces to the S1 and S2 sacral vertebrae. It invaded the right seminal vesicle, encased the right internal iliac vessels, and was inseparable from the sacral periosteum at the right upper sacral nerve root exit points. It involved the sacral foramina with no intraspinal extension but reached the sacroiliac joint (Fig. 1). These findings correlated with the oncologist's evaluation of a poor prognosis.Fig. 1Axial (left) and sagittal (right) contrast-enhanced computed tomography (CT) scan of the abdomen and pelvis demonstrating a large, destructive, osteolytic bone lesion involving the sacrum. Axial (left) and sagittal (right) contrast-enhanced computed tomography (CT) scan of the abdomen and pelvis demonstrating a large, destructive, osteolytic bone lesion involving the sacrum. Diagnosis The mechanical pain was attributed to the tumor in the sacral area, which involved the sacroiliac joint (SIJ). Initially, we performed a diagnostic SIJ injection because a sacral lesion was suspected to be the primary pain generator; however, the pain diary demonstrated no clinical benefit. When evaluating treatment alternatives, such as intrathecal chemical neurolysis or cordotomy, the patient refused any procedure carrying a risk of motor weakness or bladder/bowel dysfunction. Furthermore, phenol was not available at our institution, and intrathecal pump implants are not readily available in our country. Similarly, the Port-A-Cath option was unavailable. Placement of an epidural catheter was considered, but the limited reservoir capacity (100mL) of the available pump would have necessitated daily refills. Given that the patient resided far from the hospital, a more practical option was selected. We discussed the external catheter option with the patient, emphasizing that it is a viable and reversible technique [1]. The Multi-Disciplinary Committee (MDC) agreed, and a discussion with the patient and family regarding the alternatives and consequences resulted in informed consent after the family was given time for consideration. During this time, the patient's pain was poorly controlled, with frequent ER visits and admissions for pain crises. It required escalation of the analgesic regimen until the day of the procedure (MST 40 mg TID, MIR 10 mg PRN, Methadone 5 mg PO BID, Duloxetine 60 mg PO Q Day, Paracetamol 1g PO TID). Case report The procedure was performed in the operating room with the patient in the prone position under deep sedation, using strict aseptic technique and fluoroscopic guidance. A paramedian approach at the L2-L3 level, an intrathecal lumbar drain (0.7 mm internal diameter and 1.5 mm outer diameter) was inserted intrathecally (Lumbar Drainage Kit, MEDTRONIC™; 46419 (Fig. 22)) using a Tuohy needle (14G 11cm). The catheter tip was advanced without resistance to the T9 level using the guidewire (Fig. 3) and confirmed using anteroposterior (AP) and lateral fluoroscopic views. The proximal end was tunneled subcutaneously 20 cm laterally to the left of the entry point of the Tuohy needle. To prevent dislodgement, the externalized catheter was secured with stitches to the fixation tabs provided with the product. The catheter tip level was chosen based on the sacral tumor location, targeting the spinal segments corresponding to the back, pelvic, and lower extremity nociceptive fibers [2].Fig. 2Lumbar Drainage Kit, MEDTRONIC™; material code: 46419.Fig. 3Lateral fluoroscopic view confirming intrathecal Tuohy needle placement and the advancement of a catheter tip over a guidewire to the T9 vertebral level. Lumbar Drainage Kit, MEDTRONIC™; material code: 46419. Lateral fluoroscopic view confirming intrathecal Tuohy needle placement and the advancement of a catheter tip over a guidewire to the T9 vertebral level. Post-procedure, dressings were changed every 7–10 days in a specialized dressing room; this process required sterile gloves, chlorhexidine disinfection of the exit site, and the application of an antimicrobial dressing material for the catheter exit point using 3M™ Tegaderm™ CHG Chlorhexidine Gluconate (Fig. 4).Fig. 4 The external portion of the catheter was secured with a Luer-Lock Connector and an Integral Plug, connected to a 0.2-μm filter taken from an epidural kit (Epidural Minipack – system 1- PORTEX™ – Smiths Medical™), then into the external infusion pump (CADD-Solis™ Ambulatory Infusion System). Outcome The patient's condition improved substantially with the continuous infusion of Bupivacaine 0.5mg/mL and Fentanyl 10mcg/mL at a rate of 0.1 to 0.3mL/hr via the external pump. The patient remained on this therapy for 66 days with a 50% reduction in pain and approximately a 30% reduction in systemic opioid dosage; sleep quality improved substantially, although ambulation was not achieved. The patient was able to turn in bed with ease again. Moreover, the recurrent ER visits and hospital admissions were eliminated following the initiation of the infusion. The patient's post-procedure pain medication regimen included MST 30 mg TID, MIR 10 mg PRN, Methadone 5 mg PO BID, Gabapentin 600 mg TID, Duloxetine 60 mg PO Q Day, Paracetamol 1 g PO TID. This regimen corresponds to a reported study that showed after initiating intrathecal therapy, the “mean daily morphine equivalent dosing decreased from 360 mg/day to 48 mg/day”, a strategy that not only improves pain control but also minimizes systemic side effects [3]. Discussion The primary objective of this case report is to demonstrate that an intrathecal catheter, typically utilized by neurosurgeons for external lumbar drains, was successfully adapted for long-term continuous intrathecal analgesia. It was connected to an external pump and functioned without reported complications. In this setup, the catheter was attached to an epidural filter prior to its direct connection to the pump. Our experience aligns with other reports demonstrating the feasibility of using alternative devices for intrathecal drug delivery. This is consistent with previous reports in which an intravenous port catheter was successfully adapted to administer intrathecal morphine in a terminally ill patient [4]. Furthermore, the continuity of care—specifically frequent dressing changes using chlorhexidine gluconate IV Securement Dressings (3M Tegaderm™) approximately every 10 days—enabled long-term use without any signs of infection. The family's high level of engagement and satisfaction enabled them to maintain the catheter diligently, preventing dislodgment and ensuring the dressing remained clean and intact. This successful adaptation of the catheter system enabled the clinical staff to provide the patient's family with education necessary for home-based maintenance, which significantly reduced the burden on the healthcare system through fewer ER visits and hospital readmissions, ultimately lowering overall hospital costs [5]. It should be emphasized that this approach should not be considered the gold standard treatment, but rather as a possible solution for a specific clinical scenario. Due to limited data from a single case, as well as the associated risks such as infection, high spinal anesthesia, total spinal block, and local anesthetic systemic toxicity (LAST), further case studies are necessary to better evaluate its efficacy and safety.